Neurobiology of Aging
Volume 29, Issue 8 , Pages 1143-1159 , August 2008

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

  • Sebastiaan Engelborghs

      Affiliations

    • Department of Neurology and Memory Clinic, Middelheim General Hospital (ZNA), Lindendreef 1, 2020 Antwerp, Belgium
    • Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • ,
  • Karen De Vreese

      Affiliations

    • Innogenetics NV, Technologiepark 6, 9052 Ghent, Belgium
    • ,
  • Tom Van de Casteele

      Affiliations

    • Innogenetics NV, Technologiepark 6, 9052 Ghent, Belgium
    • ,
  • Hugo Vanderstichele

      Affiliations

    • Innogenetics NV, Technologiepark 6, 9052 Ghent, Belgium
    • ,
  • Bart Van Everbroeck

      Affiliations

    • Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • ,
  • Patrick Cras

      Affiliations

    • Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • Department of Neurology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
    • ,
  • Jean-Jacques Martin

      Affiliations

    • Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • ,
  • Eugeen Vanmechelen

      Affiliations

    • Innogenetics NV, Technologiepark 6, 9052 Ghent, Belgium
    • ,
  • Peter Paul De Deyn

      Affiliations

    • Department of Neurology and Memory Clinic, Middelheim General Hospital (ZNA), Lindendreef 1, 2020 Antwerp, Belgium
    • Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • Biobank, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
    • Corresponding Author InformationCorresponding author at: Reference Center for Biological Markers of Memory Disorders, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium. Tel.: +32 3 820 26 20; fax: +32 3 820 26 18.

Received 17 November 2006 ,Revised 19 January 2007 ,Accepted 7 February 2007.

References 

  1. American Psychiatric Association . DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch. Neurol. 2001;58:373–379
  3. Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin. Neurol. Neurosurg. 2005;107:165–173
  4. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res. Bull. 2003;61:235–242
  5. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259
  6. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed diagnoses?. Arch. Neurol. 2003;60:1696–1702
  7. Folstein M, Folstein S, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatric Res. 1975;12:189–196
  8. Fujigasaki H, Martin JJ, De Deyn PP, Camuzat A, Deffond D, Stevanin G, et al. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. Brain. 2001;124:1939–1947
  9. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch. Neurol. 1998;55:937–945
  10. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 2005;57:721–729
  11. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goemitz A, Andreasen N, et al. Measurements of phosphorylated tau epitopes in the differential diagnosis of Alzheimer's disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry. 2004;61:95–102
  12. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228–234
  13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442
  14. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using β-amyloid1–42 and tau levels in CSF. Neurology. 1999;52:1555–1562
  15. Jackson M, Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathol. 1996;91:127–134
  16. Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J. Neural Transm. Suppl. 1998;53:97–118
  17. Johnson R, Wichern D. Applied Multivariate Statistical Analysis. fifth ed.. New York: Prentice Hall; 2003;
  18. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143–1153
  19. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin. Neuropathol. 1988;7:299–305
  20. Markesbery WR. Neuropathology of Dementing Disorders. London: Arnold; 1998;
  21. McKeith IG, Galasko D, Kosoka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies. Neurology. 1996;47:1113–1116
  22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  23. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554
  24. Pickut BA, Saerens J, Mariën P, Borggreve F, Goeman J, Vandevivere J, et al. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. J. Nucl. Med. 1997;38:929–934
  25. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia; diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  26. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid beta (1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology. 2004;62:1580–1584
  27. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp G, et al. Effects of processing and storage conditions on amyloid β (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 2005;51:189–195
  28. Shoji M, Kanai M, Matsubara E, Ikeda M, Hariagaya Y, Okamoto K, et al. Taps to Alzheimer's patients: a continuous Japanese study of cerebrospinal fluid markers. Ann. Neurol. 2000;48:402
  29. Sjögren M, Vanderstichele H, Ågren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin. Chem. 2001;47:1776–1781
  30. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased b-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094–2103
  31. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association of the National Institute on Aging Working Group. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. Neurobiol. Aging. 1998;19:109–116
  32. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of β-amyloid(1–42) in cerebrospinal fluid and plasma. Int. J. Exp. Clin. Invest. 2000;7:245–258
  33. Verbeek MM, Pijnenburg YA, Schoonenboom NS, Kremer BPH, Scheltens P. Cerebrospinal fluid tau levels in frontotemporal dementia. Ann. Neurol. 2005;58:656–657
  34. Weber T. Clinical and laboratory diagnosis of Creutzfeldt-Jakob disease. Clin. Neuropathol. 2000;19:249–250

PII: S0197-4580(07)00055-3

doi: 10.1016/j.neurobiolaging.2007.02.016

Neurobiology of Aging
Volume 29, Issue 8 , Pages 1143-1159 , August 2008

Article Tools

* Image Usage & Resolution